Icrucumab
Icrucumab
Icrucumab (pronounced as i-kru-cu-mab) is a monoclonal antibody designed for the treatment of cancer. It is a type of biological therapy that targets the vascular endothelial growth factor receptor 2 (VEGFR-2), which plays a significant role in angiogenesis.
Etymology
The name "Icrucumab" is derived from the International Union of Pure and Applied Chemistry (IUPAC) nomenclature for therapeutic monoclonal antibodies. The prefix "I-" is used for the source of the antibody, in this case, it is a fully human antibody. The infix "-cru-" is not specifically defined in the IUPAC nomenclature, but it is likely related to the target or disease state. The suffix "-mab" is used for monoclonal antibodies.
Related Terms
- Monoclonal antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
- Biological therapy: Treatment to stimulate or restore the ability of the immune system to fight infection and disease.
- Vascular endothelial growth factor receptor 2 (VEGFR-2): A protein that plays a critical role in angiogenesis and vasculogenesis.
- Angiogenesis: The physiological process through which new blood vessels form from pre-existing vessels.
See Also
External links
- Medical encyclopedia article on Icrucumab
- Wikipedia's article - Icrucumab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski